{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-024720","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2024-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.060644+00:00","generated_at":"2026-06-01T02:41:34.251681+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Elite Pharmaceuticals acquires three ANDAs from Nostrum Laboratories for $900k","bullets":["Acquired ANDAs for generic Norco (hydrocodone/APAP), Percocet (oxycodone/APAP), and Dolophine (methadone) from Nostrum.","Paid $900,000 cash; also received royalty-free perpetual license for manufacturing technology.","Asset Purchase Agreement signed June 17, 2024; transaction closed June 21, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-024720","json":"https://secwatch.observer/filing/0001493152-24-024720.json","markdown":"https://secwatch.observer/filing/0001493152-24-024720.md","text":"https://secwatch.observer/filing/0001493152-24-024720.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224024720/0001493152-24-024720-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224024720/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:41:34.251681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}